The what, why and how of bayesian clinical trials monitoring

Abstract
We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5‐Fluorouracil for colorectal cancer.

This publication has 16 references indexed in Scilit: